Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

Similar articles for PubMed (Select 24718685)

1.

The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells.

Sharma S, Santiskulvong C, Rao J, Gimzewski JK, Dorigo O.

Integr Biol (Camb). 2014 Jun;6(6):611-7. doi: 10.1039/c3ib40246k.

PMID:
24718685
2.

Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells.

Sharma S, Santiskulvong C, Bentolila LA, Rao J, Dorigo O, Gimzewski JK.

Nanomedicine. 2012 Jul;8(5):757-66. doi: 10.1016/j.nano.2011.09.015. Epub 2011 Oct 22.

PMID:
22024198
3.

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.

Ehlén A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brändstedt J, Uhlén M, Pontén F, Jirström K.

J Transl Med. 2010 Aug 20;8:78. doi: 10.1186/1479-5876-8-78.

4.

NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.

Bratasz A, Selvendiran K, Wasowicz T, Bobko A, Khramtsov VV, Ignarro LJ, Kuppusamy P.

J Transl Med. 2008 Feb 26;6:9. doi: 10.1186/1479-5876-6-9.

6.

Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.

Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L.

Cancer Chemother Pharmacol. 2011 Feb;67(2):401-14. doi: 10.1007/s00280-010-1334-9. Epub 2010 May 5.

8.

XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.

Ma JJ, Chen BL, Xin XY.

Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):222-6. doi: 10.1016/j.ejogrb.2009.06.011. Epub 2009 Sep 15.

PMID:
19758744
9.

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.

Gynecol Oncol. 2004 Jul;94(1):67-73.

PMID:
15262121
11.

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.

van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA.

Oncogene. 2013 Sep 5;32(36):4284-93. doi: 10.1038/onc.2012.433. Epub 2012 Oct 8.

PMID:
23045278
12.

Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.

Solár P, Sytkowski AJ.

Cancer Lett. 2011 Oct 1;309(1):11-8. doi: 10.1016/j.canlet.2011.05.008. Epub 2011 Jun 14.

PMID:
21676537
13.

Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E.

Int J Oncol. 2000 Mar;16(3):555-60.

PMID:
10675489
14.

Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.

Henkels KM, Turchi JJ.

Cancer Res. 1999 Jul 1;59(13):3077-83. Erratum in: Cancer Res 2000 Feb 15;60(4):1150.

15.

MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.

Rao YM, Shi HR, Ji M, Chen CH.

J Huazhong Univ Sci Technolog Med Sci. 2013 Aug;33(4):567-72. doi: 10.1007/s11596-013-1160-5. Epub 2013 Aug 1.

PMID:
23904379
16.

Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action.

Ayyagari VN, Brard L.

BMC Cancer. 2014 Feb 4;14:61. doi: 10.1186/1471-2407-14-61.

17.

Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.

Wang W, Ke S, Chen G, Gao Q, Wu S, Wang S, Zhou J, Yang X, Lu Y, Ma D.

Oncol Rep. 2004 Dec;12(6):1365-70.

PMID:
15547764
18.
19.

Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.

Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R.

Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16.

PMID:
22249249
20.

"Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.

Montopoli M, Bellanda M, Lonardoni F, Ragazzi E, Dorigo P, Froldi G, Mammi S, Caparrotta L.

Curr Cancer Drug Targets. 2011 Feb;11(2):226-35.

PMID:
21158717
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk